Interested in Our Summer 2023 Programs?
Applications for our 2023 programs are now open.
We review applications and extend offers on a rolling basis.
Helping AI Conquer Cancer
Goldman Sachs is helping drive the research as advanced, accurate artificial intelligence tools are applied to cancer diagnosis.
In partnership with teams across Goldman Sachs, our Growth Equity team invests in early-stage companies with a focus on technology and innovation as a core service or differentiating advantage. Paige AI, a spin-out from Memorial Sloan Kettering Cancer Center, has created AI-driven digital pathology tools used to help diagnose and treat cancer in clinical and research settings. Since 2020, we have invested $30 million in equity in the startup.
The investment will give Paige AI critical funding to expand its research and development and corporate infrastructure. With expertise and advice from our investing team, Paige is now positioned to grow and scale their business for the future. And AI is ready to combat cancer.